News for Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad (BIO) Q2 earnings reveal key insights on July 31. Analysts predict a 43.7% EPS drop. Discover trends and performance metrics.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc.

Summary Bio-Rad Laboratories Inc (BIO), a prominent player in the life science research and clinical diagnostics sectors, has announced that it will release its

Summary Bio-Rad Laboratories Inc (BIO), a leader in life science research and clinical diagnostics, announced the launch of four new Droplet Digitalâ„¢ PCR (ddP

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of fou

Bio-Rad Laboratories, Inc. (BIO, BIO.B) has launched four new Droplet Digital PCR platforms. The expansion follows Bio-Rad's acquisition of Stilla Techn

**media[651771]**

Wells Fargo has revised its price target for Bio-Rad (BIO), lowering it to $245 from the previous $260. Despite this adjustment, the firm maintains its Equal We

Summary Bio-Rad Laboratories Inc (BIO), a prominent player in the life science research and clinical diagnostics sectors, has announced that its Chief Operating

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company'

Bio-Rad Laboratories (BIO, BIO.B), a leader in life sciences, is set to host investor meetings at the Jefferies Global Healthcare Conference. The meetin

Shares of Bio-Rad Laboratories Inc (BIO) fell 4.42% in mid-day trading on May 21. The stock reached an intraday low of $235.87, before recovering slightly to

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Ex

Bio-Rad Laboratories, Inc. (BIO, BIO.B) executives to participate in the 2025 RBC Capital Markets Global Healthcare Conference. The event will feature a

\nComprehensive SWOT analysis based on Bio-Rad Laboratories Inc's latest SEC 10-Q filing.Insight into the company's financial performance, including a decrease i

Bio-Rad Laboratories (BIO) has received an updated analyst report from UBS, where analyst Dan Leonard maintained a \

On May 2, 2025, Citigroup analyst Patrick Donnelly maintained a \

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ETCompany ParticipantsEdward Chung - Head of Investor...

Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, investors fled to shelter as hopes for another year of U.S. outperformance, driven by economic momentum and the new administration’s pro-business approach swiftly gave way to tariff fears […]